Michael Burkes Brophy Sells 2,562 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 2,562 shares of the firm’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $354,606.42. Following the transaction, the chief financial officer now owns 75,557 shares in the company, valued at $10,457,844.37. This represents a 3.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, March 17th, Michael Burkes Brophy sold 792 shares of Natera stock. The stock was sold at an average price of $146.04, for a total transaction of $115,663.68.
• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The stock was sold at an average price of $176.88, for a total transaction of $7,694,633.76.
• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The stock was sold at an average price of $176.60, for a total value of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total value of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total value of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $143.20 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The business’s fifty day moving average price is $158.15 and its two-hundred day moving average price is $151.29. The stock has a market cap of $19.36 billion, a PE ratio of -81.36 and a beta of 1.80. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. On average, analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on NTRA shares. The Goldman Sachs Group raised their target price on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Guggenheim raised their price objective on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. JPMorgan Chase & Co. boosted their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Royal Bank of Canada started coverage on Natera in a report on Thursday, March 13th. They issued an “outperform” rating and a $251.00 price target for the company. Finally, Morgan Stanley upped their price objective on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $178.12.

Hedge Funds Weigh In On Natera

Institutional investors have recently modified their holdings of the company. LRI Investments LLC purchased a new stake in Natera in the 4th quarter worth approximately $29,000. Blue Trust Inc. grew its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc increased its stake in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after buying an additional 261 shares during the period. Finally, Principal Securities Inc. boosted its stake in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after buying an additional 59 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.